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Abstract The current study was designed to determine the
beneficial effects of zinc supplementation on expressed levels
of peroxisome proliferator-activated receptor gamma (PPAR-γ)
and glucose transporter type 1 (GLUT1) genes in newborns of
women with gestational diabetes mellitus (GDM). This ran-
domized, double-blind, placebo-controlled clinical trial was
performed among 40 women with GDM. Patients were ran-
domly allocated to intake either 233 mg zinc gluconate (con-
taining 30 mg zinc) (n = 20) or a placebo (n = 20) for 6 weeks.
PPAR-γ and GLUT1 mRNA levels were quantified in umbil-
ical cord blood of newborns of women with GDM. After
6 weeks of intervention, the change in serum zinc levels was
greater in women consuming zinc than in the placebo group
(+11.1 ± 13.4 vs. −4.8 ± 17.3 mg/dL, P = 0.002). Quantitative
results of RT-PCR demonstrated that compared with the place-
bo, zinc supplementation resulted in a significant increase of
expressed levels of PPAR-γ mRNA (P < 0.001) and GLUT1
mRNA (P < 0.001) in umbilical cord blood of newborns of
women with GDM. Taken together, the current study demon-
strated that zinc supplementation for 6 weeks among GDM
women increased the mRNA levels of PPAR-γ and GLUT1
in their newborns compared with the placebo group.
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Introduction
Gestational diabetes mellitus (GDM) is defined as insulin resis-
tance or carbohydrate intolerance causing hyperglycemia with
onset or first recognition at any time during pregnancy [1].
GDM associated with several maternal complications including
preeclampsia, still birth, and requiring operative vaginal delivery
or cesarean section, as well as several fetal complications such as
prematurity, neonatal hypoglycemia, respiratory distress syn-
drome and hyperbilirubinemia [2]. In addition, hyperglycemia
and altered concentration of fatty acid derivates may result in
decreased expression of peroxisome proliferator-activated recep-
tor gamma (PPAR-γ) in the syncytiotrophoblast and the
extravillous trophoblast of GDM placentas [3]. Previous studies
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have shown that PPAR-γ modulates the expression of several
adipocyte-specific genes involved in lipid synthesis and storage,
insulin signaling, and adipokine production [4, 5].
In addition to zinc antioxidant and anti-inflammatory prop-
erties, previous studies reported that zinc appears to be essen-
tial for the protective properties of PPAR-α and PPAR-γ in
vascular endothelial cells [6, 7]. In a study by Zhang et al. [8],
it was observed that high levels of Zn supplementation in
weaned piglets increased the mRNA expression levels of
PPAR-γ. In another study, it was reported that zinc deficiency
markedly suppressed the mRNA expression of PPAR-γ [9]. In
addition, placental glucose transporter type 1 (GLUT-1) plays
an important function in transporting glucose from mother to
fetus [10]. In a study by Ueda et al. [11] was seen that expres-
sion levels of placental GLUT-1 mRNA in zinc-deficient
pregnant mice was significantly decreased than that observed
in control pregnant mice, whereas it unchanged in zinc-
supplemented pregnant mice.
The DNA-binding domains of PPARs consist of two sets of
zinc fingers [12]. The specificity and polarity of PPAR-DNA
binding seem to be due at least in part to features in the zinc
finger domains of PPARs [13].We are aware of no randomized
controlled trial that evaluated the effects of zinc supplementa-
tion on expressed levels of PPAR-γ and GLUT-1 genes in
newborns of women with GDM. We hypothesized that zinc
supplementation might affect expressed levels of PPAR-γ and
GLUT-1 genes in newborns of women with GDM. Therefore,
the present study was conducted to evaluate the beneficial ef-
fects of zinc supplementation on expressed levels of PPAR-γ
and GLUT-1 genes in newborns of women with GDM.
Subjects and Methods
Trial Design
This was a 6-week randomized, double-blind, placebo-
controlled clinical trial.
Participants
Participants were eligible for inclusion if they were 18–
40 years of age with GDM diagnosed according to the
American Diabetes Association criteria referred to the
Naghavi Clinic in Kashan, Iran, between December 2015
and April 2016. In the current study, women with GDM diag-
nosed by Bone-step^ 2-h 75-g oral glucose tolerance test
(OGTT) at 24–28-week gestation and singleton pregnancy
were included. Diagnosis of GDM was as follows: pregnant
women who met one of the following criteria were considered
as having GDM: fasting ≥92mg/dL, 1-h ≥180 mg/dL, and 2-h
≥153 mg/dL [14]. Women pregnant with preexisting diabetes,
psychiatric disease, kidney or liver diseases, chronic hyperten-
sion, hypothyroidism, or smokers were excluded.
Ethics Statements
The present trial was conducted in accordance with the
Declaration of Helsinki, and informed consent was received
from all participants. The research was approved by the ethics
committee of Kashan University ofMedical Sciences (KUMS)
and was registered in the Iranian website for registration of
clinical trials (http://www.irct.ir: IRCT201503055623N42).
Study Design
At the onset of the study, patients were first matched one-by-
one according to preintervention BMI (<25 and ≥25 kg/m2)
and weeks of gestation (<26 or ≥26 weeks). Participants were
then randomly divided into two groups to receive either zinc
supplements (n = 20) or placebo (n = 20) for 6 weeks.
Although the duration of intervention was 6 weeks, all partic-
ipants were followed up until the delivery. Participants were
requested not to change their ordinary physical activity and not
to take any nutritional supplements during the 6-week trial. All
patients completed 3-day food records and three physical ac-
tivity records at the study baseline and weeks 2, 4, and 6 of the
intervention. Daily macro- and micro-nutrient intakes were
analyzed by nutritionist IV software (First Databank, San
Bruno, CA). In the current study, physical activity was de-
scribed as metabolic equivalents (METs) in hours per day. To
determine the METs for each patient, we multiplied the times
(in hour per day) reported for each physical activity by its
related METs coefficient by standard tables [15]. Used tool
to measure physical activity was questionnaire.
Intervention
In the intervention group, participants received 233 mg zinc
gluconate (containing 30 mg zinc) supplements and group B
received placebo. Due to the lack of evidence about the ap-
propriate dosage of zinc for patients with GDM, we used
30 mg of zinc supplements based on a previous study during
pregnancy [16]. Zinc supplements and its placebos (starch)
were manufactured by Donyayeh Behesht Pharmaceutical
Company (Tehran, Iran) and Barij Essence Pharmaceutical
Company (Kashan, Iran), respectively. All zinc and placebo
tablets were provided by Barij Essence Pharmaceutical
Company in prepacked bottles numbered for each patient ac-
cording to the randomization sequence.
Treatment Adherence
Every 2 weeks, subjects were taken enough supplements and
placebos to last 3 days after their next scheduled visit and were
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instructed to return all unused supplements and placebos at
each visit. The remaining supplements and placebos were
counted and subtracted from the number provided to deter-
mine the number taken. To increase the compliance, all par-
ticipants were receiving short messages on their cell phones to
take supplements and placebos every day.
Assessment of Anthropometric Variables
A trained midwife at the maternity clinic did anthropometric
measurements at the onset of the study and end-of-trial. Body
weight and height (Seca, Hamburg, Germany) were deter-
mined while patients were minimally clothed and no shoes.
Then, BMI [weight (kg) / height2 (m)] was calculated. All
anthropometric measures were done by a trained midwife.
Outcomes
In the present study, the primary outcome was PPAR-γ and
the secondary study outcome was GLUT1.
Isolation of Lymphocyte Cells
At first, 10 ml blood samples were obtained from umbilical
cord blood of newborns of women with GDM at delivery
time. Then, lymphocyte cells were extracted from umbilical
cord blood of newborns of women with GDM using a 50 %
Percoll (Sigma-Aldrich, Dorset, UK) gradient. Thus, for pre-
paring a stock isotonic Percoll solution, osmolity of the solu-
tion was adjusted by adding one part of 10× concentrated cell
culture medium into the nine parts of Percoll. Osmolality of
the stock solution was checked by osmometer model 3300
(LabX, EI Cajon, USA). Solution of stock isotonic Percoll
(SIP) was diluted by adding normal cell culture medium.
The cells of lymphocytes which were at the interface of
Percoll and serum were removed by using a Pasteur pipette
and washed a few times with phosphate-buffered saline
(PBS). Samples were taken for cell count and viability testing
by trypan blue, RNA and DNA extraction.
Total RNA Extraction
In order to RNA extraction, the RNXplus kit (Cinnacolon,
Tehran, Iran) was used. Total RNA extraction from all pre-
pared samples was done as recommended protocol by manu-
facture. After preparation of homogenate, the cells powder was
harvested and resuspended in 1 ml of RNAXplus reagent in a
clean RNase-free tube. After incubation for 5 min at room
temperature, the sample was pipetted and subsequently treated
with addition of 200 μl of chloroform. The mixture was incu-
bated at room temperature for 5 min after shaking rigorously
for 15 s. The mixture was centrifuged at 12,000g for 15 min,
and the aqueous phase containing the RNAwas transferred to a
cleanRNase-free tube. The total RNAwas precipitated at room
temperature for 15 min. The pellet including total RNA was
washed by using 75 % ethanol and centrifuged at 7500g for
8 min. After drying ethanol, the RNA pellet was resuspended
in 50 μl or less of TE buffer. The concentration of total RNA
was calculated based on OD 260/280 rationmeasurements as a
means to means to address purity of RNA. To confirm the
integrity of extracted RNA, it was electrophoresed. RNA sus-
pension was frozen in −20 °C until cDNA making. Following
the extraction of the total RNAs from each sample, RNA quan-
tification were performed by UV spectrophotometer. Each
samples OD 260/280 ratio between 1.7 and 2.1 was intended
that shows no contamination with both protein and DNA.
First Strand cDNA Synthesis Procedure
The first strand cDNA synthesis can be performed as an indi-
vidual reaction or as a series of parallel reactions with different
RNA templates. Therefore, the reaction mixture can be pro-
vided bymerging reagents individually or a master mix can be
prepared all of the components except template RNA.
Depending on the structure of RNA templates, separate steps
for RNA denaturation and primer annealing many improve
RT-PCR results. The isolated RNA was reverse transcribed
to cDNA library using Moloney murine leukemia virus
(MMLV) reverse transcriptase (RT). Reverse transcription
was performed with random primers.
Gene Expression
Expressed levels of PPAR-γ and Glut-1 were evaluated by
quantitative RT-PCR, using the LightCycler technology
(Roche Diagnostics, Rotkreuz, Switzerland) with SYBR
gre en de t e c t i on and Amp l i con K i t (Tab l e 1 ) .
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
primers were used as a loading control (forward
AAGCTCATTTCCTGGTATGACAACG; reve r se
TCTTCCTCTTGTGCTCTTGCTGG). As template, approxi-
mately 50 ng cDNA was applied in a quantitative real-time
RT-PCR, and the signals were detected using a real-time PCR
system. All reactions were run in duplicates. All primers were
designed using Primer Express Software (Applied
Biosystems) and Beacon designer software then, purchased
from Takaposizt Company, Iran. Relative transcription levels
were calculated using Pffafi method or 2−ΔΔCT. Normalization
of gene expression data is used to correct sample-to-sample
variation. Starting material obtained from different individuals
usually varies in tissue mass or cell number, RNA integrity or
quantity, or experimental treatment. The ideal control gene
should be expressed in an unchanging fashion regardless of
experimental conditions, including different tissue or cell
types, developmental stage, or sample treatment. Because
there is no one gene that meets this criterion for every
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experimental condition, it is necessary to validate the expres-
sion stability of a control gene for the specific requirements of
an experiment prior to its use for normalization. Also,
GAPDH gene (housekeeping gene) was used for
normalization.
Assessment of Zinc Levels
A serum zinc concentration at the study baseline and 6 weeks
after intervention among GDM women was evaluated using
zinc kit (Elitech, Puteaux, France).
Randomization
Randomization assignment was done using computer-
generated random numbers. Randomization and allocation
were concealed from the researchers and participants until
the final analyses were completed. The randomized allocation
sequence, enrolling participants and allocating them to inter-
ventions were conducted by a trained staff at the clinic.
Statistical Analysis
We applied the Kolmogrov-Smirnov test to examine if vari-
ables were normally distributed. Independent samples
Student’s t test was used to detect differences in general char-
acteristics and macro- and micro-nutrients dietary intakes be-
tween the two groups. To determine the effects of zinc sup-
plementation on PPAR-γ and GLUT1 mRNA levels, we used
independent samples Student’s t test. All statistical analyses
were done using the Statistical Package for Social Science
version 17 (SPSS Inc., Chicago, IL, USA).
Results
At the study baseline, we recruited 50 patients; however,
10 subjects were excluded from the study because of not
meeting inclusion criteria (n = 6) and needed to start insu-
lin therapy (n = 4). In the current study, 40 participants
[zinc (n = 20) and placebo (n = 20)] completed the trial
(Fig. 1). On average, the rate of compliance in the present
study was high, such that 100 % of zinc supplements were
Table 1 Specific primers used
for real-time quantitative PCR Gene Primer Product size (bp) Annealing temperature (°C)
GAPDH F: AAGCTCATTTCCTGGTATGACAACG 126 61.3
R: TCTTCCTCTTGTGCTCTTGCTGG
PPAR-γ F: ATGACAGACCTCAGACAGATTG 210 54
R: AATGTTGGCAGTGGCTCAG
GLUT1 F: TATCTGAGCATCGTGGCCAT 238 62.1
R: AAGACGTAGGGACCACACAG
GAPDH glyceraldehyde-3-phosphate dehydrogenase, GLUT1 glucose transporter type 1, PPAR-γ peroxisome
proliferator-activated receptor gamma
Randomized (n=40)
Allocated to placebo (n=20)
Lost to follow-up (n=0)
Analyzed (n=20)
Allocated to intervention (n=20)
Lost to follow-up (n=0)
Analyzed (n=20)
Assessed for eligibility(n=50)
Excluded (n=10) 
- Not meeting inclusion criteria (n=6) 
- Needed to start insulin therapy (n=4) 
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Fig. 1 Summary of patient flow
diagram
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taken throughout the study in both groups. No side effects
were reported following the consumption of zinc supple-
ments in women with GDM throughout the study.
No significant difference existed in the anthropometric
measures before and after the intervention between the two
groups (data not shown).
Comparison of total calorie intake, macro- and micro-
nutrients between the two groups based on the 3-day dietary
records throughout the study no statistically significant differ-
ence was shown (data not shown).
After 6weeks of intervention, the change in serum zinc levels
was greater in women consuming zinc than in the placebo group
(+11.1 ± 13.4 vs. −4.8 ± 17.3 mg/dL, P = 0.002). Quantitative
results of RT-PCR demonstrated that compared with the place-
bo, zinc supplementation resulted in a significant increase of
expressed levels of PPAR-γ mRNA (P < 0.001) in umbilical
cord blood of newborns of women with GDM (Fig. 2).
A significant increase in expressed levels of GLUT1
mRNA (P < 0.001) in umbilical cord blood of newborns of
women with GDM following the supplementation of zinc
compared with the placebo among GDM women (Fig. 3).
Discussion
This study assessed the beneficial effects of zinc supplementa-
tion on expressed levels of PPAR-γ and GLUT1 genes in
newborns of women with GDM. The current study shown that
zinc supplementation for 6 weeks among GDM women in-
creased the mRNA levels of PPAR-γ and GLUT1 in their
newborns compared with the placebo group. To our knowl-
edge, the current study is the first that reports the beneficial
effects of zinc supplementation on expressed levels of PPAR-γ
and GLUT1 genes in newborns of women with GDM.
Pregnant and GDM women are sensitive to micronutrient
deficiency, inflammation, and various fetal and maternal aberra-
tions [17, 18]. Our study demonstrated that zinc supplementation
for 6 weeks among GDMwomen increased the mRNA levels of
PPAR-γ in their newborns compared with the placebo group. In
line with our findings, in a study by Zhang et al. [8], it was
observed that the mRNA levels of PPAR-γ were significantly
higher in all zinc treatments (250, 380, 570, and 760 mg zinc/kg
of the basal diet) in weaned piglets. In addition, zinc supplemen-
tation increased PPAR-γ expression and activation as well as
downregulated interleukin (IL)-6 expression and production in
porcine endothelial cells [9]. Previous studies have shown that
zinc deficiency induces PPAR-γ signaling, pro-inflammatory
phenotype and atherosclerosis in vascular endothelial cells and
LDL-receptor knockout mice [7, 19]. However, no significant
difference was observed for PPAR-γ activity after low-zinc in-
take (0.5–1.5 mg/kg) in mice fed with a high-fat diet [20].
PPAR-γ is a member of the nuclear receptor superfamily and
regulates the expression of several genes encoding proteins in-
volved in adipocyte differentiation, fatty acid storage and glucose
metabolism [21]. Downregulation PPAR-γ plays an important
role in the pathology of numerous diseases such as diabetes,
atherosclerosis, and cancer [22]. The mechanisms and regulation
of PPAR-γ signaling by zinc remain mostly unknown. The cur-
rent study clearly showed that zinc is critical for normal and
constitutive PPAR-γ activity and that zinc deficiency can lead
to dysfunction of PPAR-γ signaling. Previous reports have dem-
onstrated that zincmay be required for the expression of PPAR-γ
as a zinc finger protein [23, 24] because the DNA-binding do-
main of PPAR-γ contains a zinc finger motif, which plays an
important role in the specificity and polarity of PPAR receptor
DNA binding. Furthermore, the direct involvement of zinc as a
functional component of zinc fingers in the regulation of PPAR-γ
was supported by Meerarani et al. [9] study, which clearly indi-
cated that the PPAR-γ agonist-mediated downregulation of the
transcription factor NF-kB was impaired during zinc deficiency.
The current study revealed that zinc administration for
6 weeks among GDM women increased the mRNA levels
of GLUT1 in their newborns compared with the placebo
group. In a study by Ueda et al. [11], it was seen that at day
17 of gestation, the expression of placental GLUT1 mRNA
-0.5
0.0
0.5
1.0
Placebo
Zinc
P<0.001
Study groups
egnahc
dlo
F
Fig. 2 Effect of 6-week supplementation with zinc or placebo on expres-
sion ratio of PPAR-γ gene in peripheral blood mononuclear cells of
newborns of women with GDM. GDM gestational diabetes mellitus.
PPAR-γ peroxisome proliferator-activated receptor gamma
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Fig. 3 Effect of 6-week supplementation with zinc or placebo on expres-
sion ratio of GLUT1 gene in peripheral blood mononuclear cells of new-
borns of women with GDM. GLUT1 glucose transporter type 1. GDM,
gestational diabetes mellitus
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did not affect following the supplementation with zinc, but
that observed in zinc-deficient mice significantly decreased
to 70 % of that observed in control mice. However, zinc ele-
ment did not influence expressed levels of GLUT1 in C6 rat
glioma and GP8 rat brain endothelial cells [25]. Some studies
have demonstrated that neonates who had mothers with
PGDM had higher rates of neonatal hypoglycemia [26, 27].
Placental GLUT1 plays a key role in transporting glucose
from mother to fetus [10]. Therefore, supplying glucose for
use as a placental and fetal fuel may be decreased in zinc-
deficient pregnant women. In a study by Wang et al. [28], it
was demonstrated that zinc levels in serum of women with
GDM compared with normal pregnant women had a decreas-
ing trend. However, the regulation of placental GLUT1 ex-
pression remains unclear [29]. In accordance with the impor-
tance of zinc for fetal development, zinc deficiency during
pregnancy has reported that is associated with congenital
malformations and embryonic and fetal deaths [30].
Strengths of the current study were the blinding of partici-
pants and without dropout rate. The current study has some
limitations. First of the all, the duration of this study was low.
We did not continue zinc supplementation up to delivery time.
Future studies with longer duration of the intervention and big-
ger sample size are needed to confirm the validity of our find-
ings. Second, we did not evaluate the effects of zinc supple-
mentation on other expressed levels including markers related
with inflammatory factors and biomarkers of oxidative stress.
Conclusions
Taken together, the current study demonstrated that zinc sup-
plementation for 6 weeks among GDM women increased the
mRNA levels of PPAR-γ and GLUT1 in their newborns com-
pared with the placebo group. Findings of the current study
suggest that zinc supplementation may confer advantageous
therapeutic potential for patients with GDM.
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